The primary cause of early graft failure and retransplantation following pediatric LT is early hepatic artery and portal vein thrombosis. 1, 2 In the literature, rates of HAT after pediatric LT vary from 0% to 26% , 3, 4 with most series reporting rates between 3% and 10%.
| INTRODUC TI ON
The primary cause of early graft failure and retransplantation following pediatric LT is early hepatic artery and portal vein thrombosis. 1, 2 In the literature, rates of HAT after pediatric LT vary from 0% to 26% , 3, 4 with most series reporting rates between 3% and 10%. 5 A procoagulant state has been reported after pediatric LT, due to a delayed recovery of the endogenous anticoagulant synthesis by the graft 6 . It is hypothesized that this procoagulant state plays a role in the development of thrombi, thus contributing to vascular thrombosis. 1 Consequently, anticoagulants are widely used after pediatric LT to prevent this potentially life-threatening complication, 1, 3, 4, [7] [8] [9] [10] [11] [12] [13] [14] [15] but evidence for the optimal anticoagulation and antiplatelet strategy is lacking. The only published specific pediatric LT management guidelines give expert-opinions based on best-center performance 16 or high-volume center recommendations. 17 A survey inquiring 39
Studies of Pediatric LT Registry centers has given peri-transplant anticoagulation and antiplatelet recommendations based on current North American practices. 17 Thus, the primary aim of the present survey was to compile an international overview of anticoagulation and antiplatelet strategies in pediatric LT. Our secondary aim was to describe the clinical decisions underlying anticoagulation and antiplatelet strategies. Finally, we aimed to analyze associations between reported early HAT rates and anticoagulation and antiplatelet strategies, center volume, and surgeon characteristics.
Abstract
In pediatric LT, anticoagulants and antiplatelet agents are regularly used to reduce the risk of vascular thrombosis. As evidence for optimal strategy is lacking, local practices vary greatly. The present survey aimed to compile an international overview of anticoagulation and antiplatelet strategies in pediatric LT. An online survey was sent to 98 pediatric LT centers in North and South America, Europe, Asia, and Australia.
Twenty-four centers answered the survey. 20/24 (83%) use some sort of anticoagulation and antiplatelet therapy, yielding 20 different strategies. Perioperative vascular problems, size of the hepatic artery, and patient weight were the most frequent determinants of changes in anticoagulant and antiplatelet strategy. Early HAT rates were reported to be 5% or less in 79% of responding centers. Anticoagulation and antiplatelet strategies were not significantly associated with early HAT rates (P = 0.63), or with the number of pediatric LTs performed per year and center (P = 0.92). Internationally, there is a wide variety in anticoagulation and antiplatelet strategies after pediatric LT. Efforts must be made to design a prospective multicentric trial to identify the optimal antithrombotic strategy.
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| Study design
The web-based survey used a questionnaire structured in three parts: (a) systematic questions addressing details of the type of used anticoagulant and antiplatelet regimens (timing, dosage, clinical factors influencing anticoagulant choice), (b) scenario-based questions, and (c) descriptive information regarding center volume and surgeon experience, the purpose being to identify a learning curve effect.
The content of the questionnaire is available in Appendix S1.
| Development of the questionnaire
Anticoagulation and antiplatelet strategies after pediatric LT were first identified through literature search. Clinical determinants potentially affecting anticoagulation and antiplatelet strategies after pediatric LT were identified based on discussion with numerous local and international pediatric LT experts and through literature search.
The questionnaire included nine possible anticoagulant and antiplatelet drugs used in pediatric LT and the possibility to add other ("other"). It also included two scenarios where participants had to report their attitude in a specific clinical situation. Within the systematic questions and the two scenarios proposed we included nine possible determinants for anticoagulation and antiplatelet strategies after pediatric LT: weight, delay in liver function recovery, bleeding through the drains, hepatic artery diameter equal or less than 3 mm, disparity in the caliber of the arterial anastomosis, patient's age, cold ischemia time, donor to recipient weight ratio, perioperative vascular problems. Information about center and surgeon experience was also requested. Participants were asked whether they wished for follow-up.
| Format and pretesting
The website-based questionnaire (https://www.surveymonkey.com) was developed in English. To assess the validity of the questionnaire we performed the following: (a) a semi-structured interview with six pediatric LT physicians in order to ensure clarity, relevance, completeness, and accuracy of the questionnaire -modifications were suggested and changes were made accordingly; (b) nine pediatric LT physicians rated the final version for clarity, utility, validity, and redundancy (satisfied responses 89%);
(c) testing for congruency: the final questionnaire was dispensed twice, 2 weeks apart, to nine pediatric LT physicians. Overall, the correlation coefficient for the answers was 0.34, rather low, but explained by the implementation of changes in the local protocol during the study period.
| Study population
The questionnaire was mailed to 98 centers performing pediatric LT in the United States, Canada, Europe, Asia, and Australia. The survey administration followed the Dillman principles. 18 The first e-mail was sent in July 2016 and two reminder mails were sent 2 and 4 weeks later.
| Statistical analysis
Results are expressed as numbers and proportions. As our secondary objective was to identify determinants of reported early HAT rates, we categorized these rates as centers with a high rate of thrombosis (above 5%) vs centers with a low rate of thrombosis (rate of 5% and less). We tested the association between these categorized rates of thrombosis and potential risk factors (anticoagulation 
| RE SULTS

| Demographic data
The response rate was 24% (24/98). Four centers gave responses through two team members; for the four of them, responses were similar and we were able to combine them into a single response.
Respondents were from 18 countries. 50% (12/24) of the respondents were from Europe and 25% (6/24) from North America.
Seventy-five percent (18/24) of the respondents were interested in receiving the results of this survey. Reported HAT rates ranged between 1% and 5% in 79% of all centers (19/24), whereas 16% (4/24)
reported an incidence of HAT in excess of 5%. One center did not report the HAT rate. Table 1 details the characteristics of the 24 responding centers and their reported early HAT rate. Two characteristics were significantly associated with the reported early HAT rate: lower early HAT rates were seen in centers performing transplantation starting before 1990 (P = 0.04), and higher rates were reported in combined adult and pediatric surgical teams (P = 0.003). Table 2 shows the characteristics of participating surgeons and the absence of correlation with the reported early HAT rates.
| Anticoagulation and antiplatelet products and strategies after pediatric LT
Twenty (20/24) centers (83%) used some form of anticoagulation and/or antiplatelet regimen and four centers (17%) did not. The ten anticoagulant and antiplatelet products used are listed in Table 3 .
None of these strategies were associated with differences in the reported early HAT rates.
The distribution over time of the most frequently used anticoagulant and antiplatelet drugs is summarized in Figure 1 The three most frequently used drugs were acetylsalicylic acid, unfractionated heparin, and LMWH. No anticoagulation and antiplatelet strategy was significantly associated with the reported early HAT rate (P = 0.63).
Within the participating centers, 56% use the same protocol for all patients as displayed by the answers given to the clinical cases.
The remainders use the local protocols within a flexible framework adapting to certain perioperative or patient characteristics: the most frequently reported factors that changed the use of anticoagulation and antiplatelet drugs were perioperative vascular problems, hepatic artery size, and patient weight. Of note, none of these factors were associated with higher (>5%) or lower (5%) reported early HAT rates (P = 0.78, P = 0.77 and P = 0.60, respectively). However, evidence-based data is lacking regarding the protocolbased use of these therapies. 2 Despite strong expert-based recommendations published for North America in 2012 (ie intravenous dipyridamole and weight-adapted unfractionated heparin with transition to aspirin when patient taking full per oral diet 16 ), centers do not seem to adhere to these recommendations, as illustrated in the present survey. Centers not using any anticoagulant or antiplatelet therapy do not seem to have higher HAT rates.
| D ISCUSS I ON
All respondent centers reported different anticoagulation and antiplatelet strategies, despite an occasional overlap in practice.
Not only the duration of the anticoagulation and antiplatelet drugs varies, but also the timing of implementation and the rage of doses used. Furthermore, there is a wide variability in protocol application.
The diversity of the answers suggests a degree of uncertainty in the field of pediatric LT with respect to the best practice in anticoagulation and antiplatelet strategy use. This is in alignment with the reported variety of anticoagulation and antiplatelet strategies seen in the pediatric LT literature (Table 4) . Current center strategies are based on observational studies resulting in low-grade recommendations. 3, 9, 10, 17 Of note, none of the anticoagulation and antiplatelet strategies significantly influenced the rate of early HAT in our survey.
Early HAT rates are influenced by many confounding factors.
In our analysis, we investigated for potential factors, as outlined in center volume did not show a significant difference in thrombosis rates in our survey. Another important factor in surgical success is believed to be experience; it can be expected that a learning curve effect occurs during the exposure to this major surgical procedure. 25, 28 Indeed, the reported rate of early HAT significantly decreased in centers with the longest experience (>25 years). Surprising, higher rates were also reported when transplantation was performed in a combined pediatric and adult surgical program, when compared to programs accomplished solely by adult or pediatric surgeons. This seems counterintuitive, since combined experience usually improves performance. We propose that this may be due to a larger, more heterogeneous group of surgeons, diluting clinical experience. Another possible explanation might be the low number of responses and the lack of representativeness of all centers. No other characteristic of center-or surgeon-experience was significantly related to the reported rates of early HAT, maybe also due to the small sample size.
Acetylsalicylic acid is widely used after pediatric LT, and as such, widely used by participants in our survey. Yet, only a few studies have suggested that the use of antiplatelet drugs decreased the risk of early HAT . 29, 30 The number of pediatric patients included in these studies was limited. Our survey indicates that dipyridamole, which also inhibits platelet aggregation, was used alone or in association with acetylsalicylic acid after pediatric LT. To our knowledge, there are no reports on the efficacy of dipyridamole in the prevention of HAT after pediatric LT.
Heparin is the most widely used anticoagulant after pediatric LT, both in our study and in the literature. Although intensive heparin anticoagulation is thought to be beneficial in pediatric livingrelated-donor LT (ie LT with small sized hepatic artery), reports on efficacy in deceased donor LT are scarce. 3, 9 Of note, early HAT rates seem comparable between whole organ pediatric LT and technical variant LT (reduced, split and living donor grafts). 31 Consequently, one would expect heparin anticoagulation to be homogenous for all these groups and not limited solely to living-related LT.
Other factors known to contribute to early HAT, such as the donor or graft type, graft to recipient weight ratio, number of arterial reconstructions, microsurgery use, rejection episodes, 19, 28 were not included in our analysis due to the study methodology. Ideally, a multivariate analysis of all these factors, including the used anticoagulation and antiplatelet strategy, could be useful for identifying the role of anticoagulation and antiplatelet drugs in HAT.
This survey has a number of limitations. Its low response rate is a limitation in data interpretation. Nevertheless, it corresponds to the standard e-mail response rates of surveys. 32 Even if a multimode approach has been used, with conference participations, distribution of surveys printed on paper, and numerous personal contacts, this did not significantly improve the response rate. Also the small size of the subgroups makes it difficult to come to meaningful conclusions in practice recommendations. center. Even if we were not able to detect a significant difference in thrombosis rates for centers using anticoagulation and antiplatelet strategies it does not necessarily mean it is not there; but given the aforementioned limitations we did not reveal it.
To conclude, this survey documents a wide range of anticoagulation and antiplatelet strategies used after pediatric LT with in general a low rate of reported HAT. There is clearly a need for evidence-based guidelines on appropriate anticoagulation strategies after pediatric LT and efforts must be made to design a prospective multicentric trial to address this issue.
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